<DOC>
	<DOCNO>NCT01185522</DOCNO>
	<brief_summary>This prospective , observational study assess effect RoActemra/Actemra ( tocilizumab ) fatigue patient moderate severe rheumatoid arthritis inadequate response disease-modifying antirheumatic drug ( DMARDS ) anti tumor necrosis factor ( anti-TNF ) drug . Eligible patient receive RoActemra/Actemra accord standard care follow 4 month .</brief_summary>
	<brief_title>An Observational Study Impact RoActemra/Actemra Fatigue Patients With Rheumatoid Arthritis ( PEPS )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Moderate severe rheumatoid arthritis Inadequate response diseasemodifying antirheumatic drug ( DMARDS ) antiTNF ( tumor necrosis factor ) drug Hypersensitivity RoActemra/Actemra component Active infection Participation clinical trial rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>